AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
190 hedge funds and large institutions have $679M invested in AMAG Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 65 increasing their positions, 60 reducing their positions, and 20 closing their positions.
135% more call options, than puts
Call options by funds: $3.52M | Put options by funds: $1.5M
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
4% more funds holding
Funds holding: 182 → 190 (+8)
8% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 60
1.34% less ownership
Funds ownership: 127.22% → 125.88% (-1.3%)
25% less capital invested
Capital invested by funds: $900M → $679M (-$221M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.7M |
| 2 |
RA
Royce & Associates
New York
|
+$11.1M |
| 3 |
Citigroup
New York
|
+$5.65M |
| 4 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
+$4.39M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$35.4M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$9.78M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$8.4M |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$6.62M |
| 5 |
Man Group
London,
United Kingdom
|
-$4.11M |
AMAG Hedge Fund Activity: Q4 2018 in Review
190 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q4 2018, worth a combined $679M — down 25% from $900M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AMAG positions and 20 closed out — a net gain of 8 holders — while 65 added to existing stakes and 60 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $12.7M. The largest seller was Fidelity Investments, cutting an estimated $35.4M.
- 190 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q4 2018, up from 182 in Q3 2018.
- Funds reported $679M of AMAG Pharmaceuticals stock for Q4 2018, down 25% quarter-over-quarter.
- 28 funds opened new AMAG Pharmaceuticals positions in Q4 2018 and 20 closed out, a net change of +8 holders.
- The largest AMAG Pharmaceuticals buyer in Q4 2018 was Great Point Partners, an estimated $12.7M added.
- The largest AMAG Pharmaceuticals seller in Q4 2018 was Fidelity Investments, an estimated $35.4M sold.
Based on aggregated 13F filings for Q4 2018.